Neurogene (NGNE) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Neurogene (NGNE) over the past year, gaining 119.7% versus a gain of 10.4%. Over five years, STTK leads with a -52.0% price change compared with -78.3% for NGNE. Neurogene is the larger company by market cap ($458.5 million vs $454.2 million), about 1.0 times the size, while Shattuck Labs is growing revenue faster (-82.5% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | STTK |
|---|---|---|
| Share price | $22.15 | $4.46 |
| Market cap | $458.53M | $454.22M |
| 1-day change | -3.40% | -1.98% |
| YTD return | +7.52% | +22.19% |
| 1-year return | +10.42% | +119.70% |
| 5-year return | -78.33% | -51.99% |
| EPS (TTM) | $-5.03 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $1.00M |
| Revenue growth (YoY) | -100.00% | -82.52% |
| Net income (latest FY) | $-90.35M | $-48.81M |
| Operating margin | — | -5150.80% |
| Net margin | — | -4880.90% |
| 52-week high | $43.66 | $8.33 |
| 52-week low | $15.93 | $1.93 |
| Distance from 52-week high | -49.27% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.47% | +245.29% |
| Average volume | 307.78K | 1.20M |
| Shares outstanding | 20.70M | 101.84M |
| Employees | 131 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed NGNE by 109.3 percentage points over the past year.
- Shattuck Labs grew revenue faster in its latest fiscal year (-82.52% vs -100.00%).
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
NGNE vs STTK FAQ
Which is bigger, Neurogene or Shattuck Labs?
Neurogene (NGNE) is larger, with a market capitalization of $458.53M compared with $454.22M for Shattuck Labs (STTK).
Which stock has performed better over the past year, NGNE or STTK?
STTK returned +119.70% over the past 12 months, compared with +10.42% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.